Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Refametinib

Generic Name: Refametinib

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₀F_₃IN_₂O_₅S

CAS Number: 923032-37-5

Unique Ingredient Identifier: JPX07AFM0N

Overview

No overview information available.

Background

No background information available.

Indication

Investigated for use/treatment in cancer/tumors (unspecified).

Associated Conditions

No associated conditions information available.

Clinical Trials

Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma

Phase 2

Completed

Posted: 2015/01/26

Sponsor:Samsung Medical Cent...

ID:NCT02346032

Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer

Phase 1

Terminated

Posted: 2014/06/20

Sponsor:Bayer

ID:NCT02168777

Effect of Ketoconazole on the Pharmacokinetics of Refametinib

Phase 1

Completed

Posted: 2013/08/20

Sponsor:Bayer

ID:NCT01925638

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

Phase 2

Completed

Posted: 2013/08/05

Sponsor:Bayer

ID:NCT01915602

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

Phase 2

Completed

Posted: 2013/08/05

Sponsor:Bayer

ID:NCT01915589

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy